Get the Stockscreener App
0.9152
3.55%
-0.0337
Cytomed Therapeutics Ltd stock is traded at $0.9152, with a volume of 20,484.
It is down -3.55% in the last 24 hours and down -8.48% over the past month.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
See More
Previous Close:
$0.9489
Open:
$0.912
24h Volume:
20,484
Relative Volume:
0.27
Market Cap:
$10.89M
Revenue:
$248.40K
Net Income/Loss:
$-3.05M
P/E Ratio:
-3.5052
EPS:
-0.2611
Net Cash Flow:
$-3.30M
1W Performance:
+14.39%
1M Performance:
-8.48%
6M Performance:
-11.15%
1Y Performance:
-49.16%
1-Day Range:
$0.8897
$0.98
1-Week Range:
$0.7773
$0.98
52-Week Range:
$0.6801
$3.68
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
Name
Cytomed Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare GDTC vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
0.9199 | 11.23M | 248.40K | -3.05M | -3.30M | -0.2611 |
VRTX
Vertex Pharmaceuticals Inc
|
515.52 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.79 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.63 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.26 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.10 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cytomed Therapeutics Ltd Stock (GDTC) Latest News
CytoMed Therapeutics Ltd SEC Filing (Aug 11, 2026) - Stock Titan
CytoMed Therapeutics Ltd (GDTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CytoMed Therapeutics Ltd (GDTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CytoMed Therapeutics Ltd (GDTC) Institutional Confidence - TradingKey
GDTC|CytoMed Therapeutics Ltd|Price:0.880|Chg%:-0.110 - TradingKey
CytoMed Therapeutics Ltd (GDTC) Cash Flow - TradingKey
CytoMed Therapeutics Ltd (GDTC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CytoMed Therapeutics Ltd (GDTC) Balance Sheet - TradingKey
CytoMed Therapeutics Ltd (GDTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CytoMed Therapeutics Ltd (GDTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CytoMed Therapeutics Ltd (GDTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CytoMed Therapeutics Ltd (GDTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GDTC|CytoMed Therapeutics Ltd|Price:0.990|Chg%:+0.140 - TradingKey
CytoMed Therapeutics Ltd (GDTC) Valuation: PE, PB & Fair Value Analysis - TradingKey
CytoMed Therapeutics Ltd (GDTC) Income Statement - TradingKey
Form 13D/A CytoMed Therapeutics Ltd For: 24 July By Investing.com - Investing.com South Africa
CytoMed Therapeutics (GDTC) director adds 200,000 shares in July buys - Stock Titan
Form 4 CytoMed Therapeutics Ltd For: 24 July By Investing.com - Investing.com South Africa
CytoMed Therapeutics (GDTC) insider discloses two ordinary share dispositions - Stock Titan
CytoMed Therapeutics' US$1.7m Market Cap Fall Books Insider Losses - simplywall.st
CytoMed Therapeutics Ltd – An Emerging Star in Singapore’s Cancer Biotechnology Sector - FinancialContent
CytoMed Therapeutics(GDTC) Stock Options Chain | Quotes & News - Moomoo
CytoMed Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
CytoMed Therapeutics (GDTC) Stock Forecast & Analyst Ratings - Moomoo
CytoMed Therapeutics Ltd (NASDAQ: GDTC) – A Rising Star in Singapore’s Cancer Biotechnology Sector - FinancialContent
GDTCCytoMed Therapeutics Ltd Options - Finviz
CytoMed, a Singapore Biotech, RevolutionizesCancer Treatment Using Donor Immune Cells - openPR.com
CytoMed Chairman Boosts Personal Stake and Funds R&D Expansion at LongevityBank - The Globe and Mail
Form 6K CytoMed Therapeutics Ltd For: 23 June - Investing.com UK
Form 6K CytoMed Therapeutics Ltd For: 23 June By Investing.com - Investing.com Australia
CytoMed Therapeutics (NASDAQ: GDTC) chair ups exposure and funds LongevityBank R&D - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) director buys 112,000 shares in open market - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) shareholders approve all AGM proposals - Stock Titan
CytoMed Therapeutics (GDTC) Dips 2.48% as Key Support at $1.08 Comes into FocusDouble Top - newsline.com
CytoMed Therapeutics (NASDAQ: GDTC) director discloses holding 4,000 Ordinary Shares - Stock Titan
CytoMed Therapeutics LtdA Rising Star in Singapore's Cancer Biotechnology Sector - openPR.com
CytoMed Therapeutics Limited is accelerating its international expansion - openPR.com
CytoMed Therapeutics (NASDAQ: GDTC) director reports 2,469 ordinary shares on Form 3 - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) director files initial Form 3 ownership - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) director Choo Chee Kong details direct and indirect share ownership - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) CFO reports holding 25,781 ordinary shares - Stock Titan
CytoMed Therapeutics (GDTC) chair adds 112,000 shares in private purchase - Stock Titan
[144] CytoMed Therapeutics Ltd SEC Filing - Stock Titan
Cytomed Therapeutics Ltd Stock (GDTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytomed Therapeutics Ltd Stock (GDTC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Choo Chee Kong | Director |
May 13 '26 |
Buy |
1.15 |
112,000 |
128,778 |
430,324 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):